Agha Khan
Endocrinology, Diabetes & Metabolism · Pueblo, CONPI 1649336546
Payments from drug & device makers
Across 45 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$204
- Mannkind Corporation$107
- Medtronic$75
- Novo Nordisk$52
- Dexcom, Inc.$42
- IBSA Pharma Inc.$37
- plus $207 from 11 others
What the payments were for
- Food & beverage$64389%
- Education$203%
- Gifts$598%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 14 | $204 |
| Mannkind Corporation | 4 | $107 |
| Medtronic | 4 | $75 |
| Novo Nordisk | 4 | $52 |
| Dexcom, Inc. | 3 | $42 |
| IBSA Pharma Inc. | 2 | $37 |
| Amgen | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Ascendis Pharma Endocrinology Inc | 1 | $20 |
| Radius Health, Inc. | 1 | $19 |
| Senseonics, Incorporated | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| BETA Bionics, Inc. | 2 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
How this compares
$723 in reported general payments places this provider in the 35th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
See all endocrinology, diabetes & metabolism providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humulin R U-500Insulin Regular, Human | 86 | $146,347 |
| JardianceEmpagliflozin | 83 | $110,237 |
| OzempicSemaglutide | 52 | $98,001 |
| TrulicityDulaglutide | 32 | $54,160 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 16 | $44,483 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 32 | $41,265 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 64 | $31,473 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 68 | $25,232 |
| FarxigaDapagliflozin Propanediol | 13 | $13,240 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $13,123 |
| SynthroidLevothyroxine Sodium | 159 | $12,278 |
| HumalogInsulin Lispro | 15 | $7,660 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $6,034 |
| Novolog FlexpenInsulin Aspart | 23 | $5,803 |
| Insulin Lispro Protamine MixInsulin Lispro Protamin/Lispro | 15 | $5,429 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $52 | $103,08865 claims |
| Lilly USA, LLCTrulicity, Humalog, Humalog Mix 75-25, Insulin Lispro | $15 | $65,73769 claims |
| AstraZenecaFarxiga | $16 | $13,24013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
Other endocrinology, diabetes & metabolism in Pueblo
- Ana Ramirez BerliozPueblo$4K
- Satish GargAurora$8.6M
- Neda RasouliAurora$6.7M
- Viralkumar ShahAurora$2.1M
- Halis AkturkAurora$1.8M
- Leigh PerreaultBoulder$1.7M
- Daniel BessesenDenver$1.2M
- Lori GerardEnglewood$786K
- Leonard ZemelDenver$728K
- Bryan HaugenAurora$714K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.